Editor's Note: On July 27-28, 2024, the "2024 Breast Cancer Summer Forum · Northern Salon" was grandly held at Beijing Shougang Park. The conference upheld the philosophy of "learning and…

The 2024 European Society for Medical Oncology (ESMO) Annual Congress will take place from September 13th to 17th in Barcelona, Spain. As an annual celebration in the field of oncology,…

A recent study published in Clinical Cancer Research (Jan 9, 2025) highlights the potential of structural variant (SV)-based circulating tumor DNA (ctDNA) detection in early-stage breast cancer (EBC). Unlike traditional…

A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…

Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.

Antibody-drug conjugates (ADCs) have emerged as a promising treatment modality for pancreaticobiliary cancers, offering targeted delivery of cytotoxic agents while minimizing systemic toxicity. Dr. Lei Zheng’s presentation at the ASCO…